Mr. Michael King is the former CFO and CBO of PDS Biotechnology where he continues to serve as a senior advisor. Mr. King has also been a senior advisor at Akari Therapeutics, prior to which he was CFO and CBO of Aprecia Pharmaceuticals, and CBO of Atrin Pharmaceuticals. Mr. King was a member of the US Executive Committee for Sandoz GmbH, a multi-billion-dollar subsidiary of Novartis AG. A former management consultant with McKinsey & Company in its Pharmaceutical and Medical Products practice, he also has a background in corporate finance and sell-side analyst research, with deep knowledge of the pharmaceutical/biotech industry. Mr. King holds an MBA with Honors from the Columbia Graduate School of Business.